Table 2.

Selected studies evaluating scarring alopecia outcomes following IL-17 A and IL-17R inhibitor use

Author	Indication	Enrollment	Study Drug Regimen	Concurrent Therapies	Outcomes
Lobato-Berezo et al. [16]	FD	1	Ixekizumab 160 mg subcutaneous injections at week 0, 80 mg at weeks 2, 4, 6, 8, 10, 12, and 80 mg every 4 weeks from the 16 weeks	Not reported	At 16-week follow-up, there was worsening of disease with an increase in the number of pustules, crusts, and the size of the alopecic patch prompting discontinuation Treatment failure attributed to paradoxical FD reaction
Ismail et al. [27]	FD	1	Secukinumab, 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks thereafter	Ciclosporin 100 mg/day (discontinued after two months of secukinumab), minocycline 50 mg/day, topical clobetasol dipropionate 0.05%, and antiseptic shampoo	At two-month follow-up, mild clinical improvement noted At four-month follow-up, there was significant improvement with reduction in active disease No adverse effects reported
De Bedout et al. [28]	DC	1	Secukinumab, 150 mg subcutaneous monthly injections after 4 weekly loading doses	Dapsone 50 mg/day	At one-month follow-up, the patient’s drainage and pain ceased, with patient reporting regression of nodules for the first time in 6 years The patient developed an eczematous reaction after initiation of secukinumab which was treated topically and stabilized
Passeron et al. [29]	LPP	37	Secukinumab 300 mg every four weeks for 32 weeks or Placebo for 16 weeks followed by secukinumab 300 mg every 2 weeks for 16 weeks	None	Primary endpoint not met, however at week 16, IGA ≤ 2 for 37.5% of patients in secukinumab group vs. 30.8% in placebo group After switching from placebo to secukinumab every two weeks, IGA ≤ 2 for 63.6% of patients in placebo group
Maurelli et al. [30]	LPP	1	Brodalumab 210 mg every 2 weeks	Not reported	At three-month follow-up, there was complete remission of LPP lesions with disappearance of follicular hyperkeratosis and itch
Ahmed et al. [31]	LPP	1	Ixekizumab 160 mg initial dose administered subcutaneously, followed by 80 mg every 2 weeks for 12 weeks and a maintenance dose of 80 mg every 4 weeks	Topical clobetasol dipropionate alternating every two weeks with topical tacrolimus monohydrate 0.1% Discontinued at 20 weeks, and patient continued on ixekizumab monotherapy	At 12-week follow-up, the patient had a LPPAI score of 0 in comparison to an initial score of 6 (scale 1–10) as well as reduction in SALT score At 20 weeks, the patient had clinical improvement without relapse or side effects